Approval of FDCs: NPPA flags prospects of over medication, profiteering
New Delhi: The National Pharmaceutical Pricing Authority (NPPA) has recently expressed its concern over approving Fixed Dose Combinations (FDCs) of two or more drugs that may lead to "over-medication" as a potential hazard. The authority also flagged the prospect of "profiteering" by pharma companies.
This came in wake of applications moved with the drug price regulator to fix the prices of new drugs, most of which were fixed-dose combination (FDC) medicines or drug cocktails.
FDCs are medicines that combine more than one drug in a single pill, thereby, easing medication for those who are supposed to take multiple drugs as part of long-term treatment. A couple of months ago, the Drugs controller general of India (DCGI) released a list of 471 new fixed-dose combinations (FDCs) related to vitamins, minerals, and micronutrients; and directed the state Drug Controllers (DCs) to ask drug makers to get manufacturing licenses for the same.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.